EUROPA trial

EUROPA trial
Name	EUROPA trial
Acronym	EUROPA
Phase	Phase III
Condition	Coronary artery disease
Intervention	Perindopril
Control	Placebo
Status	Completed
Enrollment	12,218
Start date	1997
Completion date	2002
Primary outcome	Composite of cardiovascular death, myocardial infarction, and cardiac arrest with resuscitation

EUROPA trial The EUROPA trial was a large randomized, double-blind, placebo-controlled cardiovascular outcomes study that evaluated the effect of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease. Designed and conducted by multinational academic investigators in collaboration with industry and regulatory stakeholders, the trial influenced guideline recommendations for secondary prevention and informed subsequent trials of renin–angiotensin system blockade.

Background

The trial emerged from prior evidence including landmark trials such as HOPE (trial), CONSENSUS, SOLVD, VALIANT, and CATS that explored angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in populations defined by myocardial infarction, heart failure, and left ventricular dysfunction. Sponsors and investigators cited mechanistic and clinical data from studies at institutions like Imperial College London, Université Paris Descartes, University of Munich, University of Oxford, and regulatory discussions within European Medicines Agency and US Food and Drug Administration. Key opinion leaders who contributed to trial design had affiliations with organizations including European Society of Cardiology, American College of Cardiology, British Heart Foundation, Wellcome Trust, and professional networks across Netherlands Heart Institute and INSERM research groups.

Study Design and Methods

EUROPA was organized as a randomized, double-blind, placebo-controlled, event-driven trial enrolling 12,218 participants across multiple sites in countries such as France, United Kingdom, Germany, Italy, Spain, Netherlands, Belgium, Sweden, Denmark, Norway, and Portugal. Inclusion criteria referenced prior revascularization procedures like coronary artery bypass grafting and percutaneous coronary intervention and diagnostic imaging from centers such as Cleveland Clinic, Mayo Clinic, and university hospitals affiliated with Karolinska Institutet and University of Barcelona. The intervention compared perindopril with placebo in addition to contemporary background therapy including agents discussed in trials like CAPRICORN and CHARM. Randomization procedures and data monitoring were overseen by independent committees with standards aligned to documents from International Committee of Medical Journal Editors and CONSORT guidelines. Endpoints included a primary composite of cardiovascular death, myocardial infarction, and cardiac arrest with resuscitation, adjudicated by committees using criteria similar to those in TIMI and GRACE registries. Statistical analysis plans referenced methods from biostatisticians at London School of Hygiene and Tropical Medicine and Harvard School of Public Health.

Results

The trial reported a statistically significant reduction in the primary composite outcome favoring perindopril versus placebo, with event rates and hazard ratios presented in primary publications appearing in journals such as The Lancet, European Heart Journal, and Journal of the American College of Cardiology. Subgroup analyses examined cohorts characterized by prior percutaneous transluminal coronary angioplasty, presence or absence of left ventricular dysfunction, concomitant use of beta-blockers, aspirin, and statins, and stratified by geography including populations from Eastern Europe, Western Europe, and Southern Europe. Secondary endpoints assessed individual components like cardiovascular mortality and myocardial infarction, and exploratory analyses evaluated effects on hospitalization for heart failure and need for repeat revascularization, with comparisons framed against outcomes seen in trials such as PEACE and AIRE.

Safety and Adverse Events

Adverse event reporting detailed known class effects of angiotensin-converting enzyme inhibitors including cough, hypotension, and rare instances of angioedema, with incidence rates compared to safety findings in HOPE (trial) and SOLVD. Laboratory monitoring raised findings related to renal function and electrolytes, prompting protocol-specified dose adjustments similar to practices at Mayo Clinic and recommendations from National Institute for Health and Care Excellence. Data safety monitoring boards with representatives from World Health Organization-aligned networks reviewed unblinded data periodically, and post hoc analyses considered interactions with agents evaluated in ALLHAT and VALIANT.

Interpretation and Impact

EUROPA influenced clinical practice and guideline statements from bodies such as European Society of Cardiology, American Heart Association, American College of Cardiology, and national health agencies in France, United Kingdom, and Germany by supporting ACE inhibitor use in stable coronary disease. Health policy debates cited cost-effectiveness modeling from groups at Oxford University and health technology assessment reports by National Institute for Health and Care Excellence. The trial findings were discussed in context with mechanistic research on the renin–angiotensin system led by laboratories at University College London and translational studies from Beth Israel Deaconess Medical Center.

Subsequent Research and Legacy

EUROPA stimulated further randomized trials and meta-analyses including pooled analyses by consortia that integrated data from PEACE, HOPE (trial), and other ACE inhibitor trials, and informed research agendas at institutions like Stanford University School of Medicine and Johns Hopkins University. Its legacy includes influence on trials comparing ACE inhibitors with angiotensin receptor blockers and newer agents evaluated in trials such as PARADIGM-HF and EMPA-REG OUTCOME. Academic reviews in The Lancet, BMJ, and textbooks from publishers like Oxford University Press and Elsevier continue to cite the trial when discussing secondary prevention strategies in coronary artery disease.

Category:Clinical trials